{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262591","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.417135+00:00","generated_at":"2026-05-17T01:01:40.931394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint","bullets":["ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).","Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.","GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.","Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.","ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262591","json":"https://secwatch.observer/filing/0001193125-25-262591.json","markdown":"https://secwatch.observer/filing/0001193125-25-262591.md","text":"https://secwatch.observer/filing/0001193125-25-262591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/0001193125-25-262591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/srpt-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:01:40.931394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}